Ory Rouvio

Ory Rouvio

Auto-generated profile, based on publicly available information

Ory Rouvio

Institute of Hematology, Soroka Medical Center, Beer Sheva, Israel; Internal Medicine A and Multiple Myeloma Clinic, Soroka Medical Center, Beer Sheva, Israel

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
NONoa Ofir
Noa Ofir
EREty Rozenberg
Ety Rozenberg
OSOmri Sharabi
Omri Sharabi
MZMiri Zektser
Miri Zektser
OROry Rouvio
Ory Rouvio
Roi GazitRoi Gazit
Roi Gazit
Multiple myeloma (MM) is a bone marrow plasma cells malignancy. Despite impressive advancements of treatments, MM remains incurable due to complex clonality. Here, we present a novel 14-color flow cytometry (FACS) protocol for robust detection and visualization of MM clonality. We developed a single-tube 14-color FACS protocol to analyze fresh bone marrow samples, tested on 8 MM patients. A premixed, stable antibody cocktail was used to enhance reproducibility and streamline workflow. Dimensionality reduction technique (t-SNE) was applied to visualize plasma cell clonality. Our panel shown CD38+ CD138+ plasma cells, and their clonality. As expected, MM patients had unique clonal patterns with significant heterogeneity at primary diagnosis. Advanced t-SNE analysis provides a convenient visualization of multi-parameter heterogeneity in a unified 2-D plot. Importantly, our data presents some similarities among patients, and further differences between primary analysis and secondary relapse. Taken together, our protocol provides a robust and efficient method for improving MM diagnosis using commercially available antibodies and a standard FACS machine. Concise visualization of multi-parameter FACS will help therapeutic decisions and advance the personalized treatment strategies with emerging antigen-specific drugs.